Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.59 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10090401 | 0.95 | ELANE (0.67) | ELANECYP3A4CYP2C9 | |
| SCHEMBL10090395 | 0.92 | ELANE (0.69) | ELANECYP3A4CYP2C9CYP2C8CYP2C19 | |
| SCHEMBL10090406 | 0.90 | ELANE (0.67) | ELANECYP3A4CYP2C9 | |
| SCHEMBL10090400 | 0.90 | ELANE (0.67) | ELANECYP3A4CYP2C9 | |
| SCHEMBL10090399 | 0.89 | ELANE (0.68) | ELANECYP3A4CYP2C9 | |
| SCHEMBL8284467 | 0.88 | ELANE (0.67) | ELANECYP3A4CYP2C9 | |
| SCHEMBL8285930 | 0.86 | ELANE (0.66) | ELANECYP3A4CYP2C9CYP2C8CYP2C19 | |
| SCHEMBL10090408 | 0.86 | ELANE (0.65) | ELANECYP3A4CYP2C9 | |
| SCHEMBL333331 | 0.85 | ELANE (0.79) | ELANECYP3A4CYP2C9CYP2C8CYP2C19 | |
| SCHEMBL10090398 | 0.85 | ELANE (0.69) | ELANECYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097629-B2 | Dihydropyridinone derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-17 | — | — | US | disclosed |
| US-8097629-B2 | Dihydropyridinone derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-17 | — | — | US | disclosed |
| US-20080045541-A1 | Dihydropyridinone Derivatives | BAYER-HEALTHCARE AG (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045541-A1 | Dihydropyridinone Derivatives | BAYER-HEALTHCARE AG (DE) | 2008-02-21 | — | — | US | disclosed |
| WO-2005080372-A1 | DIHYDROPYRIDINONE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045541-A1 | Dihydropyridinone Derivatives | TNNI3, DHPS, TNNT2 | ELANE 260/4885CYP3A4 3343/4885CYP2C9 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.